NPPB and breast carcinoma: In the HERA breast cancer trial of trastuzumab, the cardiac biomarker substudy reported that increases in NT-proBNP during trastuzumab treatment were most predictive of a subsequent reduction in LV function on echocardiographic surveillance (106).